A Phase 2 interventional study of Ofatumumab and Ofatumumab in Lymphoma, Follicular, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-29.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy
Patients in the study will be randomized into two dose groups. Patients in each dose group will receive one infusion of 300 mg of HuMax-CD20 followed by 7 weekly infusions of either 500 or 1000 mg of HuMax-CD20. Disease status will be assessed every 3 months until month 24.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 116 is above the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
followed by 7 weekly infusions of 1000mg ofatumumab
Number of Participants With Objective Response (OR)
OR was assessed by an Independent endpoints Review Committee (IRC) according to the standardized response criteria for Non-Hodgkin's lymphoma. Participants with Complete Response (CR; complete disappearance of all detectable disease), Complete Response unconfirmed (CRu; any residual lymph node/nodal mass \>1.5 centimeters \[cm\] in its longest transverse diameter that regressed \>75% compared to baseline), or Partial Response (PR; \>=50% decrease in the sum of the product of diameters of indicator lesions) were defined as responders for OR.
Time frame: Start of treatment (Day 1 of Week 0) until 3 months after start of last infusion (up to Week 32)
Number of Participants Classified as Responders and Non-responders for Objective Response (OR)
Based on OR over a 6-month period from start of treatment, participants were classified as responders/non-responders as follows: participants with CR, CRu, or PR were classified as responders, whereas participants with Stable Disease (SD; achieving less than PR but not consistent with PD), Progressive Disease (PD; 50% increase from nadir in the products of the greatest perpendicular diameters of any previously identified node or appearance of any new node \>1 cm), or Not Evaluable (NE) participants were classified as non-responders.
Time frame: 6-month period from the start of treatment. There was a median time of response at Month 5.5 (participants were followed for up to 24 months).
Duration of Response
The duration of response is defined as the time from the initial response (the first visit at which response was observed) to progression or death. For participants who were lost to follow-up, duration of response was censored at the date of the last attended visit at which the endpoint was assessed. The Kaplan-Meier method was used to estimate duration of response.
Time frame: From start of treatment (Week 0) until Month 24
Progression-Free Survival
Progression-free survival (PFS) is defined as the time from randomization until the first radiologically or clinically documented evidence of progression or death due to any cause, if sooner. For participants who were lost to follow-up, PFS was censored at the date of the last attended visit at which the endpoint was assessed. The Kaplan-Meier method was used to estimate PFS.
Time frame: From start of treatment (Week 0) until Month 24
Time to Next Follicular Lymphoma (FL) Therapy
Time to next FL (anti-lymphoma) therapy is defined as the time from randomization until the time of first administration of the next anti-lymphoma therapy other than ofatumumab. For participants who were lost to follow-up, the time was censored at the date of the last attended visit at which the endpoint was assessed.
Time frame: From start of treatment (Week 0) until Month 24
Overall Survival
Overall survival is defined as the time from randomization until death. For participants who are lost to follow-up, overall survival will be censored at the date of the last attended visit at which the endpoint was assessed.
Time frame: First dose (Week 0) until 5 years
Percent Change From Screening (Visit 1) in Tumor Size as Assessed by Radiologist 1 (R1) and Radiologist 2 (R2) at Months 3, 6, 9, 12, 18, and 24
Tumor size was measured by computed tomography (CT) scan and was computed as the sum of product of diameters (SPD) for the indicator lesions. CT scans with contrast of the neck, thorax, abdomen, and pelvis were performed at Screening and during the follow-up period (Month 3, 6, 9, 12, 18, and 24). The change in tumor size from Screening (Visit 1) was presented per Radiologist 1 (R1) and Radiologist 2 (R2). Percent change from Screening (Visit 1, Week -2) = (value at Visits 11, 12, 13, 14, 16, and 18 minus the value at Visit 1 divided by the value at Visit 1) \* 100.
Time frame: Visits 1 (Week -2), 11 (Month 3), 12 (Month 6), 13 (Month 9), 14 (Month 12), 16 (Month 18), and 18 (Month 24)
Percent Change From Baseline (Visit 2) in CD19+ and CD20+ Cells in Peripheral Blood at Visits 11 and 12
CD19 and CD20 are proteins found on the cell surface of B cells, and they can be detected in peripheral blood by flow cytometry. Flow cytometry of peripheral blood was performed for immediate analysis of cells with cluster of differentiation 19 (CD19+) and CD20+. The analysis will be done until a value is reached that is in the normal range. Percent change from Baseline (Visit 2) = (value at Visits 11 and 12 minus the value at Visit 2 divided by the value at Visit 2) \* 100.
Time frame: Visits 2 (Baseline), 11 (Month 3), and 12 (Month 6)
Number of Participants With Conversion and no Conversion of BCL2 Positive to BCL2 Negative in Peripheral Blood
B-cell lymphoma 2 (BCL2) is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. BCL2 mitochondrial ribonucleic acid (mRNA) was measured by polymerase chain reaction (PCR) from peripheral blood. Participants who had no post-screening data were categorized as "Missing."
Time frame: Screening (Visit 1) until Month 24 (Visit 18)
Number of Participants Who Experienced Any Adverse Event From First Treatment (Visit 2) to Visit 18 (Month 24)
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A list of AEs experienced in the study at a frequency threshold of 5% can be found in the AE section.
Time frame: From first treatment (Visit 2) until Visit 18 (Month 24)
Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 12, 13, and 14
HAHA are indicators of immunogenicity to ofatumumab. Blood samples were withdrawn from participants at Visits 1, 12, 13, and 18 for analysis of HAHA. Analysis of HAHA was done in batches.
Time frame: Visits 1 (Screening), 12 (Month 6), 13 (Month 9), and 18 (Month 24)
Complement (CH50) Levels at Visit 1 and at the End of Infusion at Visit 2
Blood samples were drawn from participants at Visits 1 and 2 for analysis of complement (CH50) levels. Analysis of CH50 was done in batches, and CH50 levels were measured two hours after the end of study medication infusion. Percent change from Screening (Visit 1, Week -2) = (value at Visit 2 minus the value at Visit 1 divided by the value at Visit 1) \* 100.
Time frame: Visits 1 (Week -2) and 2 (Week 0)
Number of Participants Classified as Responders for Fragment C Receptor (FcR) Polymorphism (Poly.)
FcR poly. affect the affinity with which FcRs interact with immunoglobulin molecules and are prognostic factors that are indicative of altered responsiveness to treatment and/or survival. A blood sample was drawn at Visit 1 for analysis (done in batches of several samples) of FcR poly. (Fcgamma RIIIa Valine/Phenylalanine genotypes \[TT=thymidine/thymidine, TG=thymidine/guanine, GG=guanine/guanine\] and Fcgamma RIIa Arginine/Histidine genotypes \[AA=adenine/adenine, AG=adenine/guanine, GG=guanine/guanine\]). Responders must have met the criteria for CR, CRu, or PR at either Month 3 or Month 6. Fc receptor polymorphisms and C1qA-276 results are not included in this results summary.
Time frame: From first treatment (Visit 2) until Visit 12 (Month 6)
Ctrough and Cmax at the Eighth Infusion (Visit 9, Week 7)
Cmax is defined as the maximum concentration of drug in plasma samples. Ctrough is defined as the trough plasma concentration (measured concentration at the end of a dosing interval \[taken directly before the start of the next infusion\]).
Time frame: Visit 9 (Week 7; up to 10 months after dose)
AUC(0-inf) and AUC(0-168) After the Eighth Infusion (Visit 9, Week 7)
AUC is defined as the area under the ofatumumab concentration-time curve as a measure of drug exposure. AUC(0-168) is AUC from the start of infusion to 168 hours after the start of the infusion; AUC(0-inf) is AUC from the start of infusion extrapolated to infinity.
Time frame: Visit 9 (Week 7; up to 10 months after dose)
t1/2 After the Eighth Infusion (Visit 9, Week 7)
t1/2 is defined as terminal half-life, which is the time required for the amount of the drug in the body to decrease by half.
Time frame: Visit 9 (Week 7; up to 10 months after dose)
CL After the Eighth Infusion (Visit 9, Week 7)
CL is the clearance of drug from plasma, which is defined as the volume of plasma from which drug is removed per unit time.
Time frame: Visit 9 (Week 7; up to 10 months after dose)
Vss After the Eighth Infusion (Visit 9, Week 7)
Vss is the volume of distribution at steady state of ofatumumab.
Time frame: Visit 9 (Week 7; to up 10 months after dose)
| Milestone | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Started | 30 | 86 |
| Early follow-up entry | 4 | 8 |
| Completed | 2 | 8 |
| Not completed | 28 | 78 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Disease progression | 27 | 60 |
| Withdrew: Patient refusal | 1 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Patient refuses to continue with ct scan | 0 | 1 |
| Withdrew: Started alternative treatment | 0 | 6 |
| Withdrew: Suspicion of cholangiocarcinoma | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Patient progressed, return to pakistan | 0 | 1 |
| Withdrew: Non compliance | 0 | 1 |
| Milestone | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Started | 20 | 58 |
| Completed | 0 | 5 |
| Not completed | 20 | 53 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Alternative treatment | 13 | 41 |
| Withdrew: Medical reasons | 7 | 10 |
OR was assessed by an Independent endpoints Review Committee (IRC) according to the standardized response criteria for Non-Hodgkin's lymphoma. Participants with Complete Response (CR; complete disappearance of all detectable disease), Complete Response unconfirmed (CRu; any residual lymph node/nodal mass \>1.5 centimeters \[cm\] in its longest transverse diameter that regressed \>75% compared to baseline), or Partial Response (PR; \>=50% decrease in the sum of the product of diameters of indicator lesions) were defined as responders for OR.
| participants | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| CR | 0 | 1 |
| CRu | 2 | 0 |
| PR | 2 | 8 |
Based on OR over a 6-month period from start of treatment, participants were classified as responders/non-responders as follows: participants with CR, CRu, or PR were classified as responders, whereas participants with Stable Disease (SD; achieving less than PR but not consistent with PD), Progressive Disease (PD; 50% increase from nadir in the products of the greatest perpendicular diameters of any previously identified node or appearance of any new node \>1 cm), or Not Evaluable (NE) participants were classified as non-responders.
| participants | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Responders with CR | 0 | 1 |
| Responders with CRu | 2 | 0 |
| Responders with PR | 2 | 8 |
| Non-responders with SD | 9 | 43 |
| Non-responders with PD | 14 | 26 |
| Non-responders with NE | 3 | 8 |
The duration of response is defined as the time from the initial response (the first visit at which response was observed) to progression or death. For participants who were lost to follow-up, duration of response was censored at the date of the last attended visit at which the endpoint was assessed. The Kaplan-Meier method was used to estimate duration of response.
| months | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Duration of Response | 6.0 (2.9 to 6.2) | 6.0 (2.8 to 12.3) |
Progression-free survival (PFS) is defined as the time from randomization until the first radiologically or clinically documented evidence of progression or death due to any cause, if sooner. For participants who were lost to follow-up, PFS was censored at the date of the last attended visit at which the endpoint was assessed. The Kaplan-Meier method was used to estimate PFS.
| Months | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Progression-Free Survival | 3.2 (2.9 to 9.2) | 6.0 (4.4 to 9.0) |
Time to next FL (anti-lymphoma) therapy is defined as the time from randomization until the time of first administration of the next anti-lymphoma therapy other than ofatumumab. For participants who were lost to follow-up, the time was censored at the date of the last attended visit at which the endpoint was assessed.
| Months | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Time to Next Follicular Lymphoma (FL) Therapy | 4.2 (3.8 to 8.6) | 7.0 (5.5 to 9.9) |
Overall survival is defined as the time from randomization until death. For participants who are lost to follow-up, overall survival will be censored at the date of the last attended visit at which the endpoint was assessed.
| Months | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) |
Tumor size was measured by computed tomography (CT) scan and was computed as the sum of product of diameters (SPD) for the indicator lesions. CT scans with contrast of the neck, thorax, abdomen, and pelvis were performed at Screening and during the follow-up period (Month 3, 6, 9, 12, 18, and 24). The change in tumor size from Screening (Visit 1) was presented per Radiologist 1 (R1) and Radiologist 2 (R2). Percent change from Screening (Visit 1, Week -2) = (value at Visits 11, 12, 13, 14, 16, and 18 minus the value at Visit 1 divided by the value at Visit 1) \* 100.
| percent change in tumor size | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Visit 11 (Month 3), R1, n=14, 47 | 5.50 (-85.00 to 52.00) | -7.20 (-66.00 to 69.00) |
| Visit 11 (Month 3), R2, n=15, 47 | -2.10 (-84.00 to 27.00) | -8.10 (-82.00 to 56.00) |
| Visit 12 (Month 6), R1, n=7, 34 | -20.30 (-90.00 to 13.00) | -16.10 (-91.00 to 123.00) |
| Visit 12 (Month 6), R2, n=7, 33 | -39.90 (-86.00 to 29.00) | -29.80 (-83.00 to 61.00) |
| Visit 13 (Month 9), R1, n=6, 25 | -28.90 (-85.00 to 30.00) | -22.60 (-88.00 to 138.00) |
| Visit 13 (Month 9), R2, n=6, 26 | -48.30 (-84.00 to 34.00) | -39.80 (-85.00 to 91.00) |
| Visit 14 (Month 12), R1, n=4, 17 | 5.50 (-69.00 to 74.00) | -16.00 (-73.00 to 42.00) |
| Visit 14 (Month 12), R2, n=4, 18 | -14.70 (-83.00 to 63.00) | -44.60 (-91.00 to 62.00) |
| Visit 16 (Month 18), R1, n=3, 12 | 31.10 (-81.00 to 202.00) | -18.30 (-49.00 to 45.00) |
| Visit 16 (Month 18), R2, n=3, 12 | 22.90 (-87.00 to 52.00) | -28.70 (-91.00 to 50.00) |
| Visit 18 (Month 24), R1, n=2, 8 | -4.80 (-85.00 to 75.00) | -20.10 (-64.00 to 4.00) |
| Visit 18 (Month 24), R2, n=2, 8 | -14.40 (-88.00 to 59.00) | -36.50 (-92.00 to 35.00) |
CD19 and CD20 are proteins found on the cell surface of B cells, and they can be detected in peripheral blood by flow cytometry. Flow cytometry of peripheral blood was performed for immediate analysis of cells with cluster of differentiation 19 (CD19+) and CD20+. The analysis will be done until a value is reached that is in the normal range. Percent change from Baseline (Visit 2) = (value at Visits 11 and 12 minus the value at Visit 2 divided by the value at Visit 2) \* 100.
| percent change in cells | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Visit 11 (Month 3), CD19+, n=15, 42 | -100.00 (-100.00 to 0.00) | -80.1 (-100.00 to 566.00) |
| Visit 11 (Month 3), CD20+, n=15, 45 | -100.00 (-100.00 to 0.00) | -100.00 (-100.00 to 43.00) |
| Visit 12 (Month 6), CD19+, n=8, 32 | -48.80 (-100.00 to 129.00) | -19.00 (-100.00 to 838.00) |
| Visit 12 (Month 6), CD20+, n=8, 34 | -48.20 (-100.00 to 129.00) | -19.00 (-100.00 to 18.00) |
B-cell lymphoma 2 (BCL2) is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. BCL2 mitochondrial ribonucleic acid (mRNA) was measured by polymerase chain reaction (PCR) from peripheral blood. Participants who had no post-screening data were categorized as "Missing."
| participants | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Participants converted from positive to negative | 2 | 6 |
| Participants not converted | 6 | 15 |
| Missing | 3 | 10 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A list of AEs experienced in the study at a frequency threshold of 5% can be found in the AE section.
| participants | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Number of Participants Who Experienced Any Adverse Event From First Treatment (Visit 2) to Visit 18 (Month 24) | 30 | 79 |
HAHA are indicators of immunogenicity to ofatumumab. Blood samples were withdrawn from participants at Visits 1, 12, 13, and 18 for analysis of HAHA. Analysis of HAHA was done in batches.
| participants | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Visit 1 (Week -2), n=30, 85 | 0 | 0 |
| Visit 12 (Month 6), n=8, 33 | 0 | 0 |
| Visit 13 (Month 9), n=7, 24 | 0 | 0 |
| Visit 14 (Month 12), n=3, 11 | 0 | 0 |
Blood samples were drawn from participants at Visits 1 and 2 for analysis of complement (CH50) levels. Analysis of CH50 was done in batches, and CH50 levels were measured two hours after the end of study medication infusion. Percent change from Screening (Visit 1, Week -2) = (value at Visit 2 minus the value at Visit 1 divided by the value at Visit 1) \* 100.
| Units per milliliter (U/mL) | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Visit 1 (Week -2), n=30, 85 | 57.00 (10.00 to 79.00) | 54.00 (10.00 to 99.00) |
| Visit 2 (Week 0), n=30, 84 | 49.00 (10.00 to 76.00) | 49.50 (10.00 to 92.00) |
FcR poly. affect the affinity with which FcRs interact with immunoglobulin molecules and are prognostic factors that are indicative of altered responsiveness to treatment and/or survival. A blood sample was drawn at Visit 1 for analysis (done in batches of several samples) of FcR poly. (Fcgamma RIIIa Valine/Phenylalanine genotypes \[TT=thymidine/thymidine, TG=thymidine/guanine, GG=guanine/guanine\] and Fcgamma RIIa Arginine/Histidine genotypes \[AA=adenine/adenine, AG=adenine/guanine, GG=guanine/guanine\]). Responders must have met the criteria for CR, CRu, or PR at either Month 3 or Month 6. Fc receptor polymorphisms and C1qA-276 results are not included in this results summary.
| participants | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Fc Gamma IIa Genotype = AA, n=4, 9 | NA | NA |
| Fc Gamma IIa Genotype = AG, n=11, 37 | NA | NA |
| Fc Gamma IIa Genotype = GG, n=3, 12 | NA | NA |
| Fc Gamma IIIa Genotype = TT, n=5, 31 | NA | NA |
| Fc Gamma IIIa Genotype = TG, n=11, 23 | NA | NA |
| Fc Gamma IIIa Genotype = GG, n=2, 4 | NA | NA |
Cmax is defined as the maximum concentration of drug in plasma samples. Ctrough is defined as the trough plasma concentration (measured concentration at the end of a dosing interval \[taken directly before the start of the next infusion\]).
| Milligrams per liter (mg/L) | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Ctrough, n=24, 78 | 183 ± 3.40 | 447 ± 1.31 |
| Cmax, n=23, 78 | 479 ± 0.40 | 879 ± 0.45 |
AUC is defined as the area under the ofatumumab concentration-time curve as a measure of drug exposure. AUC(0-168) is AUC from the start of infusion to 168 hours after the start of the infusion; AUC(0-inf) is AUC from the start of infusion extrapolated to infinity.
| Milligrams * hour per liter (mg.h/L) | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| AUC(0-inf), n=12, 55 | 327715 ± 1.03 | 566717 ± 1.07 |
| AUC(0-168), n=19, 75 | 71513 ± 0.40 | 113622 ± 0.65 |
t1/2 is defined as terminal half-life, which is the time required for the amount of the drug in the body to decrease by half.
| hours | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| t1/2 After the Eighth Infusion (Visit 9, Week 7) | 444 ± 0.76 | 443 ± 0.64 |
CL is the clearance of drug from plasma, which is defined as the volume of plasma from which drug is removed per unit time.
| Milliliters per hour (mL/h) | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| CL After the Eighth Infusion (Visit 9, Week 7) | 7.0 ± 0.41 | 8.8 ± 0.65 |
Vss is the volume of distribution at steady state of ofatumumab.
| mL | Ofatumumab 500 mg | Ofatumumab 1000 mg |
|---|---|---|
| Vss After the Eighth Infusion (Visit 9, Week 7) | 4414 ± 0.48 | 5408 ± 0.34 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ofatumumab 500 mg | — | 6/30 (20%) | 30/30 (100%) |
| Ofatumumab 1000 mg | — | 25/86 (29.1%) | 79/86 (91.9%) |
| Ofatumumab 500 mg: Extended Follow-up Phase | — | 2/30 (6.7%) | 0/30 (0%) |
| Ofatumumab 1000 mg: Extended Follow-up Phase | — | 6/86 (7%) | 0/86 (0%) |
| Event | Ofatumumab 500 mg | Ofatumumab 1000 mg | Ofatumumab 500 mg: Extended Follow-up Phase | Ofatumumab 1000 mg: Extended Follow-up Phase |
|---|---|---|---|---|
| Disease progressionGeneral disorders | 2/30 | 4/86 | 1/30 | 3/86 |
| NeutropeniaBlood and lymphatic system disorders | 1/30 | 5/86 | 0/30 | 0/86 |
| HypothermiaGeneral disorders | 1/30 | 0/86 | 0/30 | 0/86 |
| PyrexiaGeneral disorders | 1/30 | 0/86 | 0/30 | 0/86 |
| Neutrophil count decreasedInvestigations | 1/30 | 2/86 | 0/30 | 0/86 |
| SepsisInfections and infestations | 0/30 | 1/86 | 1/30 | 1/86 |
| CystitisInfections and infestations | 1/30 | 0/86 | 0/30 | 0/86 |
| Neutropenic infectionInfections and infestations | 1/30 | 0/86 | 0/30 | 0/86 |
| Drug toxicityInjury, poisoning and procedural complications | 1/30 | 0/86 | 0/30 | 0/86 |
| Bone marrow failureBlood and lymphatic system disorders | 1/30 | 0/86 | 0/30 | 0/86 |
| Event | Ofatumumab 500 mg | Ofatumumab 1000 mg | Ofatumumab 500 mg: Extended Follow-up Phase | Ofatumumab 1000 mg: Extended Follow-up Phase |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 6/30 | 7/86 | 0/30 | 0/86 |
| NauseaGastrointestinal disorders | 6/30 | 8/86 | 0/30 | 0/86 |
| PruritusSkin and subcutaneous tissue disorders | 5/30 | 10/86 | 0/30 | 0/86 |
| RhinitisInfections and infestations | 5/30 | 4/86 | 0/30 | 0/86 |
| NasopharyngitisInfections and infestations | 5/30 | 2/86 | 0/30 | 0/86 |
| RashSkin and subcutaneous tissue disorders | 4/30 | 14/86 | 0/30 | 0/86 |
| FatigueGeneral disorders | 4/30 | 13/86 | 0/30 | 0/86 |
| UrticariaSkin and subcutaneous tissue disorders | 4/30 | 12/86 | 0/30 | 0/86 |
| HeadacheNervous system disorders | 4/30 | 7/86 | 0/30 | 0/86 |
| DizzinessNervous system disorders | 4/30 | 1/86 | 0/30 | 0/86 |
| Age, Continuous(Years) | Ofatumumab 500 mg | Ofatumumab 1000 mg | Total |
|---|---|---|---|
| Mean | 60.4 ± 10.1 | 59.7 ± 11.1 | 59.9 ± 10.8 |
| Sex: Female, Male(Participants) | Ofatumumab 500 mg | Ofatumumab 1000 mg | Total |
|---|---|---|---|
| Female | 11 | 43 | 54 |
| Male | 19 | 43 | 62 |
| Race/Ethnicity, Customized(participants) | Ofatumumab 500 mg | Ofatumumab 1000 mg | Total |
|---|---|---|---|
| Asian | 1 | 4 | 5 |
| Black or African American | 0 | 1 | 1 |
| Hispanic or Latino | 0 | 3 | 3 |
| White | 28 | 78 | 106 |
| Reunion Island Native | 1 | 0 | 1 |
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline